1st production QuiremSpheres
On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the stituto Nazionale dei Tumori hospital in Milan, Italy. There it was used for the treatment of a patient suffering from hepatocellular carcinoma (HCC). QuiremSpheres® are radioactive microspheres for SIRT and are based on the isotope holmium-166.
Voor meer informatie: http://www.quirem.com/
Other news
Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers
Klaudia Cybulska (postdoc radiochemistry) has written an article about Huntington's Disease. Abstra...
RTM receives marketing authorisation for Fludeoxyglucose (18F)
We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018....
Production of novel diagnostic radionuclides in small medical cyclotrons
Employees from RTM and Radboudumc have published a new article: 'Production of novel diagnostic radi...
First Patient Dosed with TLX250-CDx in Italy for ccRCC
The below product is manufactured at RTM First Patient dosed with TLX250-CDx in Italy for ccRCC Th...
Interested in a collaboration?
Contact us to discuss the possibilities.